Theodore R. Schroeder - 30 Sep 2022 Form 4 Insider Report for Nabriva Therapeutics plc (NBRVF)

Role
Chief Executive Officer, Director
Signature
/s/ Dan Dolan, by power of attorney
Issuer symbol
NBRVF
Transactions as of
30 Sep 2022
Transactions value $
-$10
Form type
4
Filing time
04 Oct 2022, 21:31:52 UTC
Previous filing
07 Sep 2022
Next filing
11 Oct 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NBRVF Ordinary Shares Tax liability -$10 -5 -0.04% $2.08 12.5K 30 Sep 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units.
F2 The number of ordinary shares reported on this Form 4 reflects a 1-for-25 reverse stock split effected on September 15, 2022.